Movement Alert|Cardinal Health Rises 3.29% in Pre-Market Trading, Q4 Earnings Beat Expectations with $5 Billion Buyback Plan Announced

Market Focus08-11 18:57

On August 11, Cardinal Health rose 3.29% in pre-market trading, trading at $242.6 per share, with turnover of approximately $420,300.

The movement was driven by the company releasing fiscal Q4 results that significantly exceeded expectations, alongside a substantial capital return initiative. Cardinal Health reported Q4 adjusted EPS of $2.91, beating the consensus estimate of $2.42 by approximately 20%. While quarterly revenue of $63.672 billion came in slightly below the $65.029 billion estimate, earnings strength overshadowed the top-line miss.

More critically, the company issued fiscal 2027 forward guidance with adjusted EPS of $12.40 to $12.60, well above the FactSet consensus estimate of $12.08. Simultaneously, the board of directors approved an incremental $5 billion stock repurchase authorization, significantly enhancing the company's overall buyback capacity and providing financial flexibility to actively manage its capital structure. The company also maintained its quarterly dividend at $0.5158 per share. The combination of a substantial earnings beat, above-consensus guidance, and an aggressive buyback program collectively propelled the stock higher in pre-market trading.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment